TY - JOUR
T1 - Cytomegalovirus viremia in solid organ transplantation
T2 - Does the initial viral load correlate with risk factors and outcomes?
AU - Levitsky, Josh
AU - Freifeld, Alison G.
AU - Puumala, Susan
AU - Bargenquast, Kim
AU - Hardiman, Penny
AU - Gebhart, Catherine L
AU - Wrenshall, Lucy
AU - Langnas, Alan
AU - Kalil, Andre C.
PY - 2008/3
Y1 - 2008/3
N2 - Consistent data for using CMV quantitative PCR (QnPCR) on initial presentation to predict outcomes after solid organ transplantation (SOT) are lacking. Recipients with measurable CMV QnPCR and either CMV-V (asymptomatic viremia) or CMV-D (symptomatic CMV infection) were analyzed over 24months. Risk factors and outcomes were evaluated in relation to initial QnPCR by regression analysis and time-to-event curves. Twenty-eight recipients were identified: five CMV-V, 23 CMV-D. Patients with CMV-D had a higher median initial QnPCR (230 000 copies/mL) compared with CMV-V (2500 copies/mL; p < 0.05). No patients with CMV-V had an initial QnPCR > 10 000 copies/mL compared with 83% of the CMV-D (p = 0.004). The initial QnPCR was higher (250 000 copies/mL) in patients who did not clear CMV PCR than those who cleared (8000 copies/mL) after 14d of treatment (p = 0.03). Risk factors and indirect CMV effects were not associated with initial QnPCR. Our results highlight the importance of the initial CMV QnPCR in relation to the development of symptomatic CMV and a slower response to therapy. Alternatively, late asymptomatic viremia and recurrent CMV are associated with lower PCR levels and a low likelihood to progress and result in clinical disease.
AB - Consistent data for using CMV quantitative PCR (QnPCR) on initial presentation to predict outcomes after solid organ transplantation (SOT) are lacking. Recipients with measurable CMV QnPCR and either CMV-V (asymptomatic viremia) or CMV-D (symptomatic CMV infection) were analyzed over 24months. Risk factors and outcomes were evaluated in relation to initial QnPCR by regression analysis and time-to-event curves. Twenty-eight recipients were identified: five CMV-V, 23 CMV-D. Patients with CMV-D had a higher median initial QnPCR (230 000 copies/mL) compared with CMV-V (2500 copies/mL; p < 0.05). No patients with CMV-V had an initial QnPCR > 10 000 copies/mL compared with 83% of the CMV-D (p = 0.004). The initial QnPCR was higher (250 000 copies/mL) in patients who did not clear CMV PCR than those who cleared (8000 copies/mL) after 14d of treatment (p = 0.03). Risk factors and indirect CMV effects were not associated with initial QnPCR. Our results highlight the importance of the initial CMV QnPCR in relation to the development of symptomatic CMV and a slower response to therapy. Alternatively, late asymptomatic viremia and recurrent CMV are associated with lower PCR levels and a low likelihood to progress and result in clinical disease.
UR - http://www.scopus.com/inward/record.url?scp=41049111211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41049111211&partnerID=8YFLogxK
U2 - 10.1111/j.1399-0012.2007.00778.x
DO - 10.1111/j.1399-0012.2007.00778.x
M3 - Article
C2 - 18339143
AN - SCOPUS:41049111211
SN - 0902-0063
VL - 22
SP - 222
EP - 228
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 2
ER -